183 related articles for article (PubMed ID: 25970265)
1. Structures of potent anticancer compounds bound to tubulin.
McNamara DE; Senese S; Yeates TO; Torres JZ
Protein Sci; 2015 Jul; 24(7):1164-72. PubMed ID: 25970265
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
3. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly.
Clément MJ; Jourdain I; Lachkar S; Savarin P; Gigant B; Knossow M; Toma F; Sobel A; Curmi PA
Biochemistry; 2005 Nov; 44(44):14616-25. PubMed ID: 16262261
[TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization and molecular dynamic simulation of β-sitosterol as a tubulin-binding anticancer agent.
Mahaddalkar T; Suri C; Naik PK; Lopus M
Eur J Pharmacol; 2015 Aug; 760():154-62. PubMed ID: 25912799
[TBL] [Abstract][Full Text] [Related]
5. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
[TBL] [Abstract][Full Text] [Related]
6. CXI-benzo-84 reversibly binds to tubulin at colchicine site and induces apoptosis in cancer cells.
Rai A; Gupta TK; Kini S; Kunwar A; Surolia A; Panda D
Biochem Pharmacol; 2013 Aug; 86(3):378-91. PubMed ID: 23747346
[TBL] [Abstract][Full Text] [Related]
7. HMBA depolymerizes microtubules, activates mitotic checkpoints and induces mitotic block in MCF-7 cells by binding at the colchicine site in tubulin.
Chatterji BP; Banerjee M; Singh P; Panda D
Biochem Pharmacol; 2010 Jul; 80(1):50-61. PubMed ID: 20302847
[TBL] [Abstract][Full Text] [Related]
8. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity.
Niu L; Yang J; Yan W; Yu Y; Zheng Y; Ye H; Chen Q; Chen L
J Biol Chem; 2019 Nov; 294(48):18099-18108. PubMed ID: 31628188
[TBL] [Abstract][Full Text] [Related]
9. Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers.
Barbier P; Dorléans A; Devred F; Sanz L; Allegro D; Alfonso C; Knossow M; Peyrot V; Andreu JM
J Biol Chem; 2010 Oct; 285(41):31672-81. PubMed ID: 20675373
[TBL] [Abstract][Full Text] [Related]
10. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
11. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
[TBL] [Abstract][Full Text] [Related]
12. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
Bhattacharyya B; Panda D; Gupta S; Banerjee M
Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
[TBL] [Abstract][Full Text] [Related]
13. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
[TBL] [Abstract][Full Text] [Related]
14. Microtubules and Cell Division: Potential Pharmacological Targets in Cancer Therapy.
Sebastian J; Rathinasamy K
Curr Drug Targets; 2023; 24(11):889-918. PubMed ID: 37519203
[TBL] [Abstract][Full Text] [Related]
15. MT119, a new planar-structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation.
Zhang Z; Meng T; Yang N; Wang W; Xiong B; Chen Y; Ma L; Shen J; Miao ZH; Ding J
Int J Cancer; 2011 Jul; 129(1):214-24. PubMed ID: 20830720
[TBL] [Abstract][Full Text] [Related]
16. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.
Alday PH; Correia JJ
Biochemistry; 2009 Aug; 48(33):7927-38. PubMed ID: 19586046
[TBL] [Abstract][Full Text] [Related]
17. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
18. Insight into the GTPase activity of tubulin from complexes with stathmin-like domains.
Wang C; Cormier A; Gigant B; Knossow M
Biochemistry; 2007 Sep; 46(37):10595-602. PubMed ID: 17711308
[TBL] [Abstract][Full Text] [Related]
19. The determinants that govern microtubule assembly from the atomic structure of GTP-tubulin.
Nawrotek A; Knossow M; Gigant B
J Mol Biol; 2011 Sep; 412(1):35-42. PubMed ID: 21787788
[TBL] [Abstract][Full Text] [Related]
20. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents.
Kim ND; Park ES; Kim YH; Moon SK; Lee SS; Ahn SK; Yu DY; No KT; Kim KH
Bioorg Med Chem; 2010 Oct; 18(19):7092-100. PubMed ID: 20810285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
